“FC Bayern Basketball stands for success, commitment and team spirit – values that Creapure® also embodies,” explains Andreas Niedermaier, CEO of the Alzchem Group.”We are proud to support the team ...

The new biosensor device is designed to test for symmetric dimethylarginine, a chemical compound released in the early stages ...

USA: An interim analysis of the Phase 3 VISIONARY study revealed that sibeprenlimab achieved a significant and clinically ...

FDA approval of MIPLYFFATM and product launch cap third quarter filled with multiple commercial and clinical development milestones Zevra ...

Proceeds expected to support the upcoming planned launches and fund the continued development of Niktimvo and revumenibExpected to fund Syndax ...

Almost half of adults and children with neurofibromatosis type 1 (NF1) responded to the investigational MEK inhibitor ...

Syndax Pharmaceuticals and Royalty Pharma plc today announced that Syndax has entered into a $350 million synthetic royalty funding agreement with Royalty Pharma based on U.S. net sales ...

Proceeds expected to support the upcoming planned launches and fund the continued development of Niktimvo and revumenibExpected to fund Syndax through profitability; proforma cash approaching $800 mil ...

Pharmaceuticals announced the outcome of the U.S. Food and Drug Administration Endocrinologic and Metabolic Drugs Advisory ...

WALTHAM, Mass. and NEW YORK, Nov. 4, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX) and Royalty Pharma plc (Nasdaq: RPRX) today announced that Syndax has entered into a $350 million ...

Announced Exclusive Licensing Agreement with Viatris for Sotagliflozin in all Markets Outside of the U.S. and Europe Completed ZYNQUISTA™ FDA Advisory Committee Meeting; PDUFA Goal Date December 20, ...

Opens in a new tab or window Share on X ... the adjusted geometric mean 24-hour urinary protein-to-creatinine ratio (UPCR) was 38.3% (95% CI 26.0-48.6, two-sided P<0.001) lower with iptacopan ...